{"id":42615,"date":"2018-12-18T21:23:28","date_gmt":"2018-12-18T19:23:28","guid":{"rendered":"https:\/\/newserver.fyb.de\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/"},"modified":"2018-12-18T21:23:28","modified_gmt":"2018-12-18T19:23:28","slug":"htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/","title":{"rendered":"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics"},"content":{"rendered":"<p>Martins\u00adried \u2014 <strong>High-Tech Gr\u00fcn\u00adder\u00adfonds<\/strong> and <strong>Think.Health Ventures<\/strong>, toge\u00adther with <strong>busi\u00adness angels<\/strong>, invest <strong>3.3 million euros<\/strong> in a <strong>Series A for<\/strong> the growth of <strong>PreO\u00admics<\/strong> in Martins\u00adried. PreO\u00admics deve\u00adlops and produ\u00adces inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies for the preana\u00adly\u00adtics of samples for mass spec\u00adtro\u00adme\u00adtry. Today, sample proces\u00adsing for mass spec\u00adtro\u00adme\u00adtry is usually perfor\u00admed accor\u00adding to home\u00admade proto\u00adcols. These proces\u00adses are slow, not repro\u00addu\u00adci\u00adble, not robust and cannot be auto\u00adma\u00adted. These solu\u00adti\u00adons are ther\u00ade\u00adfore very time-consum\u00ading and costly, which can even lead to the loss of valuable samples.<\/p>\n<p>PreO\u00admics addres\u00adses these issues through a stan\u00addar\u00addi\u00adzed tech\u00adno\u00adlogy that enables robust and repro\u00addu\u00adci\u00adble results in sample prepa\u00adra\u00adtion. Addi\u00adtio\u00adnally, the proto\u00adcols have a signi\u00adfi\u00adcantly redu\u00adced workload compared to tradi\u00adtio\u00adnal prac\u00adti\u00adces. As part of the seed invest\u00adment with High-Tech Gr\u00fcn\u00adder\u00adfonds and busi\u00adness angels, the first products were brought to market and new products were deve\u00adlo\u00adped. For this purpose, foun\u00adders Garwin Pich\u00adler and Nils Kulak have built up a team at the IZB faci\u00adli\u00adties in Martins\u00adried and formed part\u00adner\u00adships for produc\u00adtion and further deve\u00adlo\u00adp\u00adment. Think.Health Ventures is now leading another finan\u00adcing round of \u20ac3.3 million to support the further inter\u00adna\u00adtio\u00adna\u00adliza\u00adtion of the busi\u00adness and the deve\u00adlo\u00adp\u00adment of addi\u00adtio\u00adnal products.<\/p>\n<p>Dr. Garwin Pich\u00adler, Mana\u00adging Direc\u00adtor at PreO\u00admics, said, \u201cCusto\u00admers world\u00adwide use our tech\u00adno\u00adlo\u00adgies that enable stan\u00addar\u00addi\u00adzed and effi\u00adci\u00adent sample prepa\u00adra\u00adtion for protein analy\u00adsis and offer a signi\u00adfi\u00adcant cost-bene\u00adfit advan\u00adtage. With the new capi\u00adtal, we intend to acce\u00adle\u00adrate the expan\u00adsion of global sales with a focus on the U.S. and the deve\u00adlo\u00adp\u00adment of new products.\u201d<\/p>\n<p>Dr. Fabian Mohr, Invest\u00adment Mana\u00adger at HTGF: \u201cWe are very exci\u00adted to co-invest in the Series A to build on the success of the seed round. The company has made a great deve\u00adlo\u00adp\u00adment and we trust in the leader\u00adship team for further market expan\u00adsion and product development.\u201d<\/p>\n<p>For <strong>Dr. Michael Ruoff (photo), part\u00adner at Think Health Ventures<\/strong>, the main factor contri\u00adbu\u00adting to the invest\u00adment was \u201cthe effec\u00adtive solu\u00adtion to a clear problem with posi\u00adtive market feed\u00adback combi\u00adned with the exper\u00adtise and ambi\u00adtion of the entire team.\u201d \u201cWe see great poten\u00adtial with PreO\u00admics to acce\u00adle\u00adrate drug deve\u00adlo\u00adp\u00adment for serious dise\u00ada\u00adses, as their products curr\u00adently have an outstan\u00adding market position.\u201d<\/p>\n<p><strong>About PreO\u00admics<\/strong><br>\nThe company was spun out in August 2016 with intellec\u00adtual property from Matthias Mann\u2019s lab at the Max Planck Insti\u00adtute of Bioche\u00admis\u00adtry. Since then, new products have been deve\u00adlo\u00adped, which have been protec\u00adted with their own IP. The mana\u00adging direc\u00adtors Garwin Pich\u00adler and Nils Kulak are supported by an advi\u00adsory board with a wealth of expe\u00adri\u00adence in the life scien\u00adces. PreO\u00admics\u2019 mission is to bring the gold stan\u00addard for preana\u00adly\u00adtics in mass spec\u00adtro\u00adme\u00adtry to market.<\/p>\n<p><strong>About High-Tech Gr\u00fcnderfonds<\/strong><br>\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start\u00adups with growth poten\u00adtial. With a total volume of 892.5 million euros distri\u00adbu\u00adted across three funds and an inter\u00adna\u00adtio\u00adnal part\u00adner network, HTGF has alre\u00adady supported more than 500 start\u00adups since 2005. His team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and startup experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups in the hard\u00adware, soft\u00adware, life scien\u00adces and chemi\u00adcal indus\u00adtries. More than \u20ac1.9 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in around 1,400 follow-on finan\u00adcing rounds to date. In addi\u00adtion, the fund has now successfully sold shares in 100 companies.<\/p>\n<p>Inves\u00adtors in the public-private part\u00adner\u00adship include the German Fede\u00adral Minis\u00adtry for Econo\u00admic Affairs and Energy, KfW, the Fraun\u00adho\u00adfer-Gesell\u00adschaft and the busi\u00adness enter\u00adpri\u00adses ALTANA, BASF, Bayer, Boeh\u00adrin\u00adger Ingel\u00adheim, B.Braun, Robert Bosch, B\u00dcFA, CEWE, Deut\u00adsche Post DHL, Dr\u00e4ger, Dril\u00adlisch AG, EVONIK, EWE AG, Haniel, Hettich, Knauf, K\u00f6rber, LANXESS, media + more venture Betei\u00adli\u00adgungs GmbH &amp; Co. KG, PHOENIX CONTACT, Post\u00adbank, QIAGEN, RWE Gene\u00adra\u00adtion SE, SAP, Schufa, Schwarz Gruppe, STIHL, Th\u00fcga, Vector Infor\u00adma\u00adtik, WACKER and Wilh. Werhahn KG.<\/p>\n<p><strong>About Think.Health.com<\/strong><br>\nThink.Health invests as a boutique risk-taker in health\u00adcare ventures. We conti\u00adnuously seek inno\u00adva\u00adtions and disrup\u00adtive busi\u00adness models in digi\u00adtal health\u00adcare, medi\u00adcal tech\u00adno\u00adlo\u00adgies and health service provi\u00adders. We typi\u00adcally invest in early stage ventures and growth oppor\u00adtu\u00adni\u00adties ranging from \u20ac 200k to \u20ac 2m. We are an active and hands-on inves\u00adtor and provide strong support to our manage\u00adment&nbsp;teams.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Martins\u00adried \u2014 High-Tech Gr\u00fcn\u00adder\u00adfonds and Think.Health Ventures, toge\u00adther with busi\u00adness angels, invest 3.3 million euros in a Series A for the growth of PreO\u00admics in Martins\u00adried. PreO\u00admics deve\u00adlops and produ\u00adces inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies for the preana\u00adly\u00adtics of samples for mass spec\u00adtro\u00adme\u00adtry. Today, sample proces\u00adsing for mass spec\u00adtro\u00adme\u00adtry is usually perfor\u00admed accor\u00adding to home\u00admade proto\u00adcols. These processes&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":42625,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364],"tags":[],"class_list":["post-42615","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","news-category-venture-capital-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics - FYB Financial Yearbook<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"Martins\u00adried \u2014 High-Tech Gr\u00fcn\u00adder\u00adfonds and Think.Health Ventures, toge\u00adther with busi\u00adness angels, invest 3.3 million euros in a Series A for the growth of PreO\u00admics in Martins\u00adried. PreO\u00admics deve\u00adlops and produ\u00adces inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies for the preana\u00adly\u00adtics of samples for mass spec\u00adtro\u00adme\u00adtry. Today, sample proces\u00adsing for mass spec\u00adtro\u00adme\u00adtry is usually perfor\u00admed accor\u00adding to home\u00admade proto\u00adcols. These proces\u00adses [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2018-12-18T19:23:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"600\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics\",\"datePublished\":\"2018-12-18T19:23:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\"},\"wordCount\":693,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg\",\"articleSection\":[\"General\",\"Featured\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\",\"url\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\",\"name\":\"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg\",\"datePublished\":\"2018-12-18T19:23:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg\",\"width\":600,\"height\":465},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics - FYB Financial Yearbook","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/","og_locale":"en_US","og_type":"article","og_title":"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics - FYB Financial Yearbook","og_description":"Martins\u00adried \u2014 High-Tech Gr\u00fcn\u00adder\u00adfonds and Think.Health Ventures, toge\u00adther with busi\u00adness angels, invest 3.3 million euros in a Series A for the growth of PreO\u00admics in Martins\u00adried. PreO\u00admics deve\u00adlops and produ\u00adces inno\u00adva\u00adtive tech\u00adno\u00adlo\u00adgies for the preana\u00adly\u00adtics of samples for mass spec\u00adtro\u00adme\u00adtry. Today, sample proces\u00adsing for mass spec\u00adtro\u00adme\u00adtry is usually perfor\u00admed accor\u00adding to home\u00admade proto\u00adcols. These proces\u00adses [&hellip;]","og_url":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2018-12-18T19:23:28+00:00","og_image":[{"width":600,"height":465,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics","datePublished":"2018-12-18T19:23:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/"},"wordCount":693,"commentCount":0,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg","articleSection":["General","Featured"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/","url":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/","name":"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg","datePublished":"2018-12-18T19:23:28+00:00","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2018\/12\/a-mr.jpg","width":600,"height":465},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/htgf-and-think-health-ventures-series-a-3-3-million-euros-for-the-growth-of-preomics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"HTGF and Think.Health Ventures: Series A 3.3 million euros for the growth of PreOmics"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42615","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=42615"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/42615\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/42625"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=42615"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=42615"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=42615"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}